SKIP TO CONTENT
about abbott
contact
International | eng
Country Language
International | eng
Country Language

JETi™ Hydrodynamic Thrombectomy System

Peripheral Thrombectomy Device

Single-session treatment of lower extremity venous thrombosis using a novel thrombectomy device

Single-session treatment of lower extremity venous thrombosis using a novel thrombectomy device

Overview: Retrospective Pilot Study

Khalsa et al., JVIR. 2020.

Objective
To study the efficacy of the JETi™ Peripheral Thrombectomy System in treating acute venous thrombosis.

Methods
Retrospective review of 40 total procedures in 30 patients with acute lower extremity venous thrombosis (25 iliocaval, 20 iliofemoral and 15 femoropopliteal segments).

Primary Endpoints
Technical Success Rate defined as reestablishment of inline flow.

Additional Endpoints
Percent thrombus removal, total thrombolytic dose, total procedural time, overnight thrombolysis post procedure, ICU length of stay, total hospital length of stay, procedure related complications, mean symptom duration and venous segments treated.

Clinical Outcomes

JETi™ Peripheral Thrombectomy System achieved a 93% overall technical success rate with 77% of patients successfully treated in a single-session. Patients treated with JETi™ in a single-session required less TPA and shorter ICU stays compared to those treated with overnight CDT. 

 

 Single-Session JETi™ Thrombectomy
(n = 23/30)		Overall JETi™ Thrombectomy*
(n = 30/30)
Mean ICU Length of Stay1.1 days1.6 days
Mean TPA Dose3.1 mg7.8 mg
Mean Thrombus Removal81.2%74.0%

 

*Data includes 7 patients requiring overnight CDT.

Restoration of inline flow was successfully achieved in 77% of patients in a single session.

JETI Restoration of Inline Flow

Single-session restoration of flow was associated with shorter ICU stays and a 60% lower dose of TPA when compared with overnight CDT.

JETi Shorter ICU Stays and Lower TPA Data

Technical success was achieved in 93% of patients treated with the JETi™ Thrombectomy System.

JETi Technical Success Data for Lower Extremity Venous Thrombosis

Reference:

Khalsa et al., JVIR. 2020.

MAT-2209358 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2023 Abbott. All Rights Reserved.

MAT-2001111 v5.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

MAT-2305078 v1.0